Pulmonx (LUNG) Competitors

Cerus (NASDAQ:CERS) and Pulmonx (NASDAQ:LUNG) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, community ranking, analyst recommendations, valuation, risk, dividends, media sentiment and institutional ownership.

Does the MarketBeat Community favor CERS or LUNG?

Cerus received 536 more outperform votes than Pulmonx when rated by MarketBeat users. Likewise, 72.30% of users gave Cerus an outperform vote while only 45.21% of users gave Pulmonx an outperform vote.

Company	Underperform	Outperform
Cerus	Outperform Votes 569 72.30%	Underperform Votes 218 27.70%
Pulmonx	Outperform Votes 33 45.21%	Underperform Votes 40 54.79%

Which has more risk and volatility, CERS or LUNG?

Cerus has a beta of 1.2, meaning that its stock price is 20% more volatile than the S&P 500. Comparatively, Pulmonx has a beta of 0.68, meaning that its stock price is 32% less volatile than the S&P 500.

Do analysts rate CERS or LUNG?

Cerus currently has a consensus target price of $3.63, indicating a potential upside of 102.51%. Pulmonx has a consensus target price of $14.67, indicating a potential upside of 116.00%. Given Pulmonx's stronger consensus rating and higher probable upside, analysts plainly believe Pulmonx is more favorable than Cerus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cerus	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75
Pulmonx	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.83

Is CERS or LUNG more profitable?

Cerus has a net margin of -11.19% compared to Pulmonx's net margin of -72.01%. Cerus' return on equity of -37.90% beat Pulmonx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cerus	-11.19%	-37.90%	-10.35%
Pulmonx	-72.01%	-53.88%	-33.47%

Do institutionals & insiders have more ownership in CERS or LUNG?

78.4% of Cerus shares are held by institutional investors. Comparatively, 91.0% of Pulmonx shares are held by institutional investors. 3.4% of Cerus shares are held by insiders. Comparatively, 5.7% of Pulmonx shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Which has stronger earnings & valuation, CERS or LUNG?

Cerus has higher revenue and earnings than Pulmonx. Cerus is trading at a lower price-to-earnings ratio than Pulmonx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cerus	$156.37M	2.13	-$37.49M	-$0.11	-16.27
Pulmonx	$68.68M	3.90	-$60.84M	-$1.47	-4.62

Does the media refer more to CERS or LUNG?

In the previous week, Pulmonx had 1 more articles in the media than Cerus. MarketBeat recorded 3 mentions for Pulmonx and 2 mentions for Cerus. Cerus' average media sentiment score of 1.91 beat Pulmonx's score of 0.08 indicating that Cerus is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cerus	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Pulmonx	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Cerus beats Pulmonx on 10 of the 18 factors compared between the two stocks.